BioLines Weekender
BioLines Weekender To Our New Jersey Life Sciences Community: Welcome to the Weekender. It's been quite a week for New Jersey, and for the BioNJ Team. The good news included Bridgewater-based BioNJ Member Helsinn Group and Eisai Inc. receiving Food and Drug Administration (FDA) approval AKYNZEO® and Morris Plains-based BioNJ Member Immunomedics, Inc. announcing that the European Medicines Agency (EMA) has granted orphan drug status for one of the company's solid-tumor antibody-drug conjugates. Add to that the fact that on Monday and Tuesday BioNJ's 2nd Annual CEO Summit TOOK IT to the TOP with 250 participants, and maybe it was more than a pretty good week. Our great thanks to all who contributed to the CEO Summit. Enjoy the news below and your weekend. Because Patients Can't Wait, The BioNJ Team Highlights include: BioNJ Calendar - Stay Tuned for Registration Information for the Annual Dinner Meeting BioNJ News - Seeking Dr. Sol J. Barer Award Nominations; BIO 2015: The Road Leads through NJ NJ Industry News - FDA Approves AKYNZEO®; Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock; Advaxis Appoints Chief Medical Officer; The Opening Of Paramesh Banerji Life Sciences Homeopathic Medicine Manufacturing Facility in New Jersey; Bone Biologics Corp. Completes its Reverse Merger; FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine; Immunomedics Announces European Orphan Drug Designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment; TrialScope Appoints Chief Financial Officer; Law Firm Prepares for Myriad of Virus-Related Questions; Horizon Blue Cross Blue Shield of New Jersey Creates Groundbreaking Patient-centered Program for Cancer Treatment; Cancer Genetics Inc. Granted Patent; New Jersey Companies Make Donations in Fight Against Ebola ; StateBook International Signs Choose Charter Members; Lexicon and Ipsen Enter into Ex-North America/Japan Licensing and Commercialization Agreement; Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology; Article by James Golubieski for NMS Management Funding News - Register Today for a Free Webinar About NCATS Small Business Funding Industry Events - NSF SBIR Program & 1-to-1 Appointments; IPT 2014 Pharma/Life Science Regional SALT Seminar NJ University/Institution News - Rutgers Business School Executive Education is Offering a MiniMBA with a 10 Percent Discount Extended to BioNJ Members BioNJ Business Solutions: Office Depot Offers HP OfficeJet Pro X Buy One Get One Offer; BioNJ's Purchasing Consortium; Purchasing Consortium Highlighted at CEO Summit Talent News - LSTN at BioNJ Job Leads; Rutgers University Camden - Internship Fair BioNJ Tweets of the Week - A New Section Featuring Notable Tweets of the Week BioNJ Calendar BioNJ Legal Forum November 18, 2014 NPS Pharma Bedminster, NJ By Invitation Only Drug Development Primer December 11-12, 2014 The Conference Center at Mercer West Windsor, NJ Register Now BioNJ Annual Dinner Meeting February 5, 2015 Hilton East Brunswick East Brunswick, NJ Registration Coming Soon BioNJ News Seeking Dr. Sol J. Barer Award Nominations BioNJ is seeking nominations for its most prestigious award, The Dr. Sol J. Barer Award for Vision Innovation and Leadership. Named for Sol J. Barer, Ph.D., the former Chairman of Celgene Corporation of Summit, NJ, the Award recognizes outstanding biotechnology industry business leaders who have made significant contributions to the growth and prosperity of the industry in New Jersey and throughout the world. The Award will be presented on February 5, 2015 at the 2015 BioNJ Annual Dinner Meeting at the Hilton East Brunswick in East Brunswick, NJ. To submit a nomination, please describe in 250 words or less why the nominee should be considered for the Dr. Sol J. Barer Award. Information provided in the nomination should address, but is not limited to: Nominee's contribution to his or her company and/or organization, i.e., establishing an innovative new organization, moving an established organization forward, mentoring employees, etc. Nominee's contributions to New Jersey's Life Sciences Community. Nominee's contributions to the community on a local, State, national or global basis. The final selection of the honoree will be based upon a review of applications by the BioNJ Board of Trustees. In making a submission, please indicate the Nominee's Full Name, Company, Title and Contact Information. Please also include your Full Name, Company, Title and Contact Information. Nominations must be submitted to BioNJ via email at [email protected] by close of business on Friday, October 31, 2014. If you have any questions, please contact BioNJ Headquarters by phone at 609-890-3185 or by email at [email protected]. BIO 2015: The Road Leads through NJ BioNJ and Choose New Jersey have reserved premium space on the BIO 2015 trade show floor! We are working to incorporate the New Jersey Story into our pavilion and want to see how we might include you! INTERESTED IN LEARNING MORE ABOUT THE NEW JERSEY PAVILION? Please contact Debbie Mennito at BioNJ by phone at 609-890-3185 or by e-mail [email protected]. NJ Industry News Make sure to send us your stories via [email protected]. FDA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting Bridgewater-based BioNJ Member Helsinn Group and Eisai Inc. announced on October 13 that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is the first approved fixed combination oral agent that targets two critical signaling pathways associated with CINV by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule for the prevention of CINV. Please click here to read the full press release. Celator(R) Pharmaceuticals Announces Pricing of a $12.9 Million Public Offering of Common Stock and Warrants to Purchase Common Stock Ewing-based BioNJ Member Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, announced on October 23 the pricing of an underwritten public offering of 6,611,150 shares of common stock and warrants to purchase up to 661,115 shares of its common stock. Please click here to read the full press release. Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer Princeton-based BioNJ Member Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced October 13 that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs. In his role as Chief Medical Officer, Dr. Mauro will oversee the Company's clinical immuno-oncology programs that utilize bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), to actively suppress key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack. Please click here to read the full press release. The Opening Of Paramesh Banerji Life Sciences Homeopathic Medicine Manufacturing Facility in New Jersey, USA BioNJ Member Paramesh Banerji Life Sciences, LLC held an opening event on October 14 to mark the commissioning of their Advanced Homeopathic Medicine Manufacturing Facility in Notrh Brunswick, NJ, USA. The company was founded by Dr. Paramesh Banerji of Kolkata (Calcutta), India. Please click here to read the full press release. Bone Science Company Bone Biologics Corp. Completes its Reverse Merger Bone Biologics Corp., which is developing a protein for use in bone regenerative medicine tied to spinal fusion, announced on October 16 that the reverse merger that formed the company has been completed. Please click here to read the full article. FluoroPharma Announces That Data From Its Phase II Clinical Trial of 18-F FCPHA (CardioPET) Was Presented at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 19, 2014, in Gothenburg, Sweden Montclair-based FluoroPharma Medical, Inc., a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced on October 20 that new Phase II data related to CardioPET (18-F FCPHA) for the assessment of myocardial perfusion and fatty acid uptake in coronary artery disease (CAD) patients was presented by Dr. Fabian Demeure, an author of the abstract, at the session: Cardiovascular System: Cardiac PET Imaging on October 19th at the Annual Congress of the European Association of Nuclear Medicine (EANM), October 18 - 22, 2014, in Gothenburg, Sweden. Please click here to read the full press release. Immunomedics Announces European Orphan Drug Designation for Isactuzumab Govitecan for Pancreatic Cancer Treatment MorrisPlains-based BioNJ Member Immunomedics, Inc., announced on October 20 that the European Medicines Agency (EMA) has granted orphan drug status for one of the Company's solid-tumor antibody-drug conjugates (ADCs), isactuzumab govitecan, or IMMU-132, for the treatment of pancreatic cancer. Please click here to read the full press release. TrialScope Appoints Richard Guinaldo as Chief Financial Officer TrialScope, a Jersey City-based provider of clinical trial solutions and services, announced on October 21 that it has named Richard Aguinaldo its Chief Financial Officer. Please click here to read the full article. Global Ebola Task Force: Law Firm Prepares for Myriad of Virus-Related Questions The law firm Reed Smith on October 21 launched a multidisciplinary Global Ebola Task Force, headed by Patrick E. Bradley, a partner in the firm's Princeton office, to keep the firm abreast of legal issues that arise from the Ebola crisis and to address the questions the firm has begun fielding from clients across a wide range of industries. Please click here to read the full article. Horizon Blue Cross Blue Shield of New Jersey Creates Ground-breaking Patient-centered Program for Cancer Treatment Horizon Blue Cross Blue Shield of New Jersey announced on October 21 that it has joined with Regional Cancer Care Associates (RCCA) - one of the nation's largest oncologist physician groups - to create an Episode of Care (EOC) program to deliver highly specialized care for breast cancer patients. RCCA physicians, more than 100 specialists at 24 New Jersey locations, will be compensated on the quality, not quantity, of care their breast cancer patients receive. Please click here to read the full press release. Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers Rutherford-based BioNJ Member Cancer Genetics, Inc., an emerging leader in DNA-based diagnostics, announced on October 21 that it has received a formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its genomic probe set used to detect biomarkers indicative of HPV-associated precancer and cancer of the cervix, anus, vulva, vagina, penis, oropharynx, and pharynx. US Patent 8,865,882 covers the four-probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT®), which identifies genomic aberrations associated with progression to cancer. The patent issuance underscores the uniqueness of CGI's FHACT® test, which is currently available for clinical use in cervical cancer screening, and benefits the product's positioning in the cervical cancer diagnostics market. Please click here to read the full press release. BioNJ Members Among New Jersey Companies to Make Donations in Fight Against Ebola As U.S. hospitals and airports confront the unfolding Ebola crisis, BioNJ Members are among the companies with a presence in New Jersey that are making donations to help those stricken with the disease in West African nations and providing funds to partners in Africa to combat the virulent virus. Please click here to read the full article. StateBook International Signs Choose New Jersey, East Kentucky Power Cooperative and the Worcester Chamber of Commerce as Charter Members On the heels of its partnership with SelectUSA, the federal level government entity charged with showcasing the United States as the world's premier business location, StateBook International, the first online marketplace to unite Economic Development Organizations, site selectors and communities nationwide, today announced that Choose New Jersey, East Kentucky Power Cooperative and the Worcester Regional Chamber of Commerce have all signed agreements to utilize the StateBook International platform to plan and drive economic expansion and growth across public, private and utility interests in 2015. Please click here to read the full press release. Lexicon and Ipsen Enter into Ex-North America/Japan Licensing and Commercialization Agreement for Telotristat Etiprate BioNJ Members Ipsen and Lexicon Pharmaceuticals, Inc. on October 22 announced that they have entered into an exclusive licensing agreement for Ipsen to commercialize telotristat etiprate outside of North America and Japan, with a focus on the treatment of carcinoid syndrome. Lexicon retains sole rights to commercialize telotristat etiprate in the United States, Canada and Japan. Please click here to read the full press release. Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology A new medical imaging method being developed at BioNJ Member Rutgers University could help physicians detect cancer and other diseases earlier than before, speeding treatment and reducing the need for invasive, time-consuming biopsies. Please click here to read the full article. Mission-Related Investing: The Road from Bonds and Fixed Income to Venture Capital - An Article by James Golubieski for NMS Management In 1830, when Harvard College and Massachusetts General Hospital sued the Armories, few could have imagined the evolution in investment policy that-over the next century and a half-would free the not-for-profit community to expand its asset base and program reach to where it is today. A quick look back illustrates how far we have come, and puts into perspective the breadth of opportunities we now have to increase not only the financial, but the social impact of each dollar we invest. Please click here to read the full article. Funding News Register Today for a Free Webinar About NCATS Small Business Funding Register today to join NCATS and BIO on October 27 for a webinar on how NCATS can support small businesses and technology transfer organizations as they develop and discover new therapies and diagnostics to help move bench research to clinical practice and commercialization. The webinar is free and open to BioNJ members and other interested small businesses, research organizations, and venture-backed companies. Leaders from BIO and the NIH SBIR and STTR programs will discuss: Program overviews: Benefits of NCATS funding Tips for submitting a successful application Key NCATS focus areas to advance clinical research and patient care Upcoming opportunities and deadlines Other resources and programs, including the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs. Register today to take advantage of this exciting opportunity! Featured speakers: Cartier Esham, Ph.D., Executive Vice President for Emerging Companies, Biotechnology Industry Organization Lili M. Portilla, M.P.A., Director, Strategic Alliances, NCATS, NIH, U.S. Department of Health and Human Services Matthew Portnoy, Ph.D., SBIR and STTR Program Coordinator, NIH, U.S. Department of Health and Human Services Click here to Register for the webinar. Industry Events NSF SBIR Program & 1-to-1 Appointments An NSF focused SBIR training program sponsored by the New Jersey Small Business Development Centers and EisnerAmper LLP along with sponsoring organizations BioNJ, NJ Technology Council and the Rutgers University Office of New Ventures & Entrepreneurship will be held on Friday, October 31, from 8:30 a.m. to 1:00 p.m., at the NJIT Enterprise Development Center, in Newark. This half-day seminar is intended to provide participants with an introduction and overview of the SBIR and STTR programs including how to search for solicitations and topics that may fit their technologies and core technical competencies. The seminar will also include detailed instruction intended to help attendees prepare competitive grant proposals. It will feature an introduction to NSF's SBIR and STTR program by NSF Program Director Steven Konsek. Steven will also be available for 1-to-1 appointments with attendees in the afternoon following a networking lunch. The NSF SBIR program is very broad in its scope and is likely to be of interest to entrepreneurs working in most of the science and engineering disciplines. It has large Biological and Biomedical Technologies components, see http://www.nsf.gov/eng/iip/sbir/topicshome.jsp. Please click here for more information. IPT 2014 Pharma/Life Science Regional SALT Seminar The Institute for Professionals in Taxation (IPT) will hold a Regional, State and Local Tax (SALT) seminar on November 20 and 21 in Iselin, NJ, featuring BioNJ President and CEO Debbie Hart. The life sciences industry faces a wide-array of industry specific challenges, including in the tax area. From start-up, through commercialization, and including large, established, multi-national companies, these industries are often impacted differently by tax laws than other industries. State and local taxes are often the most significant, and most manageable, tax burdens faced by the industry. This advanced two-day seminar is designed for state and local tax professionals involved in the Pharmaceutical, Biotechnology and Life Sciences industries. The speakers, well-known experts in the state and local tax field, will focus their presentations on current state and local tax issues and how they specifically impact the life sciences industries. A wide range of topics will be presented, including income/franchise taxes, sales/use taxes, and unclaimed property. Issues to be addressed include nexus, apportionment, audit resolution, and opportunities and pitfalls - all geared towards the special challenges faced by the life sciences industries. This special focused seminar provides an opportunity to hear some of the top SALT professionals discuss current topics and their relevance to life sciences businesses, making it a "must-attend" for those state and local tax professionals in these industries. Please click here to view the full brochure. Please click here to register. NJ University/Institution News Rutgers Business School Executive Education is Offering a MiniMBA: BioPharma Innovation in Three Convenient Formats this Fall, with a 10% Discount Extended to BioNJ Members! You can choose between a week-long accelerated program, a 10-week evening program, or a convenient online program. Seats for BioNJ members are still available. The Rutgers MiniMBA: BioPharma Innovation educates clinicians and others in the life sciences industry about business operations in the Pharmaceutical and Biotechnology sectors. It is the perfect professional development opportunity for anybody who seeks a broader, cross-functional understanding of the world in which new drugs, devices and technologies are developed and brought to market. For more information, contact Jennie Fine at 848-445-9418 or [email protected], or follow the links below. 10-week evening program, starting October 13 12-week, self-paced online program, starting November 3 1-week accelerated program, starting November 17 BioNJ Business Solutions Are Spending Issues Keeping You Up at Night? BioNJ's Purchasing Consortium Can Help! Take Advantage Of Member Savings On Overhead Spending Including Office Supplies And Products, Shipping And .....Coming Soon...Health Insurance, Payroll And Event And Meeting Planning! From Fisher Lab Supplies to Business Wire Services, Insurance and IT Services and Scientific Publications - why struggle with increasing costs? Exploit your BioNJ Member Benefits and make sure you are using all the discounts that you are entitled to! For more information on your Member Benefits contact Linda Pontell at [email protected]. This Week's Featured Consortium Supplier What's Your Appetite for Risk? Receive Member Discounts on the Chubb Group! Business Insurance/Risk Management For more than 20 years, the Chubb Group has provided cost-effective risk management and insurance coverages tailored to the unique requirements of biotechnology companies. * Clinical Trials Liability Insurance * Products Liability Insurance * Professional Liability Insurance * Property & Casualty Insurance Chubb's insurance professionals specialize in the biotechnology market; they understand your issues and anticipate future insurance coverage challenges. To learn more about the program, including coverages and premium rates, contact a Chubb appointed insurance agent or broker. For more information on Chubb and all the savings available to you, contact Linda Pontell [email protected] and 609-890-3185 x104. BioNJ Purchasing Consortium Highlighted at CEO Summit Dynamic Strategies, BioNJ's newest addition to the Purchasing Consortium awarded an IT security Scan for a lucky attendee at the recent CEO Summit on Tuesday. Darek Hahn, of Dynamic Strategies said the organization is pleased to be a part of BioNJ's Member cost saving program, and thrilled to sponsor such a impressive meeting. Helen Cooke, an executive coach and founder of Cooke Consulting, won Dynamic Strategies's prize of an IT vulnerability scan for her business. Cooke Consulting Group, LLC, which specializes in guiding biotech and pharma leaders in strengthening their people skills, has recently joined BioNJ as a Platinum member. Helen commented, "The CEO Summit was impressive. Al Altomari, Jan Campbell, and the entire committee delivered an educational and timely program. To then win Dynamic Strategies' vulnerability scan was a lovely bonus!" BioNJ Talent Network Job Leads BioNJ can help you find the perfect candidate for your open positions. Call us today! Please click here to view all the job postings on the LSTN at BioNJ website. Rutgers University Camden - Internship Fair You are invited to participate in the campus-wide Internship Fair sponsored by the Career Fair of Rutgers-Camden. The Internship Fair will give you the opportunity to meet and talk with students from a wide range of majors in our College of Arts and Sciences and our School of Business. These students are interested in gaining career related experience and will be eager to learn more about your organization and internship opportunities. Please click here for more information and registration. BioNJ Tweets of the Week @YankeePR Tweeted #NPS #pharma Nader @BioNJ_Org CEO Summit: it's time to declare war on #Alzheimers & #diabetes @TFuller0 Tweeted @BioNJ_Org CEO Summit; Great culture starts w/ personal responsibility for finding a way to make a significant contribution each/every day. @MegTirrell Tweeted "Potentially a revolution in the treatment of Crohn's disease," $CELG COO Mark Alles says of '0301 at BioNJ CEO Summit Please contact BioNJ at [email protected] or 609-890-3185 with any questions. Connect with us:
© Copyright 2024